Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Pierce Biotechnology Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners. The prosecution activity is distributed across distinct art units. These figures indicate that the company's active matters are spread among multiple reviewers and administrative divisions. This distribution provides a variety of examiner perspectives within the Biotechnology & Pharmaceuticals sector.
NGUYEN, NAM P is the busiest examiner for the company and is responsible for 1 pending office action. This busiest examiner pending count of 1 is less than the total count of pending office actions. Because the workload is split, the company's prosecution success does not depend on a single examiner. Practitioners must manage different examination styles across the distinct examiners and art units. This arrangement requires a strategy that accounts for the specific requirements of each assigned reviewer. The current prosecution profile is characterized by this distribution of matters across the staff.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
| BROOKS, KREGG T | 1 | 57.1% | +1.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18229553 | COMPONENTS FOR SEPARATING MOLECULES AND METHODS OF MAKING AND USING THE SAME | BROOKS, KREGG T | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18380388 | COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE | NGUYEN, NAM P | 26d |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| 1764 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18380388 | COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE | NGUYEN, NAM P | 1678 | §103 | Final Rejection | 26d | Pending | Oct 16, 2023 |
| 18229553 | COMPONENTS FOR SEPARATING MOLECULES AND METHODS OF MAKING AND USING THE SAME | BROOKS, KREGG T | 1764 | §103§112 | Non-Final OA | 5d overdue | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPierce Biotechnology Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nam P Nguyen has the most, with 1 of Pierce Biotechnology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.